| Long-term outcomes of imatinib treatment for chronic myeloid leukemia A Hochhaus, RA Larson, F Guilhot, JP Radich, S Branford, TP Hughes, ... New England Journal of Medicine 376 (10), 917-927, 2017 | 1325 | 2017 |
| Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial A Hochhaus, G Saglio, TP Hughes, RA Larson, DW Kim, S Issaragrisil, ... Leukemia 30 (5), 1044-1054, 2016 | 919 | 2016 |
| Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib TP Hughes, G Saglio, HM Kantarjian, F Guilhot, D Niederwieser, G Rosti, ... Blood, The Journal of the American Society of Hematology 123 (9), 1353-1360, 2014 | 308 | 2014 |
| Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. U Rodeck, K Melber, R Kath, HD Menssen, M Varello, B Atkinson, ... Journal of investigative dermatology 97 (1), 20-26, 1991 | 219 | 1991 |
| Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma HD Menssen, A Sakalová, A Fontana, Z Herrmann, C Boewer, T Facon, ... Journal of Clinical Oncology 20 (9), 2353-2359, 2002 | 206 | 2002 |
| The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced … M Johannsen, G Spitaleri, G Curigliano, J Roigas, S Weikert, ... European journal of cancer 46 (16), 2926-2935, 2010 | 199 | 2010 |
| Expression of the oncofetal ED-B–containing fibronectin isoform in hematologic tumors enables ED-B–targeted 131I-L19SIP radioimmunotherapy in Hodgkin … S Sauer, PA Erba, M Petrini, A Menrad, L Giovannoni, C Grana, B Hirsch, ... Blood, The Journal of the American Society of Hematology 113 (10), 2265-2274, 2009 | 197 | 2009 |
| Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2 C Schliemann, A Palumbo, K Zuberbühler, A Villa, M Kaspar, E Trachsel, ... Blood, The Journal of the American Society of Hematology 113 (10), 2275-2283, 2009 | 181 | 2009 |
| Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors U Rodeck, M Herlyn, HD Menssen, RW Furlanetto, H Koprowski International journal of cancer 40 (5), 687-690, 1987 | 180 | 1987 |
| A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma TK Eigentler, B Weide, F de Braud, G Spitaleri, A Romanini, A Pflugfelder, ... Clinical Cancer Research 17 (24), 7732-7742, 2011 | 178 | 2011 |
| Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina J Wang, ZX Shen, G Saglio, J Jin, H Huang, Y Hu, X Du, J Li, F Meng, ... Blood, The Journal of the American Society of Hematology 125 (18), 2771-2778, 2015 | 134 | 2015 |
| ED-B fibronectin as a target for antibody-based cancer treatments A Menrad, HD Menssen Expert opinion on therapeutic targets 9 (3), 491-500, 2005 | 132 | 2005 |
| Wilms' tumour gene 1 (WT1) in human neoplasia U Keilholz, HD Menssen, A Gaiger, A Menke, Y Oji, Y Oka, ... Leukemia 19 (8), 1318-1323, 2005 | 115 | 2005 |
| Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours G Spitaleri, R Berardi, C Pierantoni, T De Pas, C Noberasco, C Libbra, ... Journal of cancer research and clinical oncology 139, 447-455, 2013 | 114 | 2013 |
| Isolated limb perfusion with the tumor‐targeting human monoclonal antibody–cytokine fusion protein L19‐TNF plus melphalan and mild hyperthermia in patients with locally … F Papadia, V Basso, R Patuzzo, A Maurichi, A Di Florio, L Zardi, E Ventura, ... Journal of surgical oncology 107 (2), 173-179, 2013 | 113 | 2013 |
| Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells T Dietrich, T Hucko, C Schneemann, M Neumann, A Menrad, J Willuda, ... Atherosclerosis 220 (2), 329-336, 2012 | 84 | 2012 |
| Expression of the WT1 Wilms' tumor gene by normal and malignant human melanocytes U Rodeck, A Bossler, C Kari, CW Humphreys, T Györfi, J Maurer, E Thiel, ... International journal of cancer 59 (1), 78-82, 1994 | 84 | 1994 |
| Wilms' Tumor Gene Expression in Human CD34+ Hematopoietic Progenitors During Fetal Development and Early Clonogenic Growth HD Menssen, HJ Renkl, M Entezami, E Thiel Blood, The Journal of the American Society of Hematology 89 (9), 3486-3486, 1997 | 80 | 1997 |
| Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia HD Menssen, HJ Renkl, U Rodeck, C Kari, S Schwartz, E Thiel International journal of cancer 70 (5), 518-523, 1997 | 76 | 1997 |
| Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies PA Erba, M Sollini, E Orciuolo, C Traino, M Petrini, G Paganelli, ... Journal of nuclear medicine 53 (6), 922-927, 2012 | 75 | 2012 |
